Motrin viral suffers digital slings and arrows

Share this article:
J&J's Motrin viral ad
J&J's Motrin viral ad
In a reminder that the new media world is not without its perils, Johnson & Johnson is backpedaling from a Motrin campaign about slings aimed at moms that drew arrows from the Stroller Mafia.

Viral ads online and print ads in magazines appealed to achy moms sore from carrying their kids in slings. But the tongue-in-cheek campaign sparked a storm of spoof response videos and cranky ripostes on Twitter.

Kathy Widmer, VP marketing for McNeil Consumer Healthcare, wrote on the company's JNJ BTW blog that the Motrin maker was taking the ads down, while noting that some print ads were already on newsstands.

“This weekend, a lot was said about Motrin on Twitter and in the blogosphere,” said Widmer. “Unfortunately, it was not the kind of conversation that we here at McNeil had hoped to be at the center of.”

Widmer noted that much of the ire centered on the ads' snarky take on the practice of “baby wearing.” The viral ad's narrator says: “Supposedly it's a real bonding experience. They say that babies carried close to the body tend to cry less than others. But what about me?”

“It was meant to engender sympathy and appreciation for all that parents do for their kids, but did so through an attempt at humor that missed the mark and many moms found offensive.”

“One bright spot is that we have learned through this process—in particular, the importance of paying close attention to the conversations that are taking place online.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...